Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 14.39M | 15.03M | 13.80M | 16.02M | 16.89M | 13.07M |
Gross Profit | 8.05M | 9.02M | 8.27M | 10.02M | 12.60M | 10.41M |
EBITDA | -13.43M | -10.55M | -16.68M | -24.36M | -19.54M | -11.24M |
Net Income | -14.32M | -11.14M | -13.58M | -23.84M | -20.29M | -12.06M |
Balance Sheet | ||||||
Total Assets | 26.03M | 15.28M | 10.73M | 13.72M | 33.69M | 25.33M |
Cash, Cash Equivalents and Short-Term Investments | 4.40M | 6.26M | 1.64M | 3.52M | 24.03M | 18.21M |
Total Debt | 11.58M | 1.51M | 2.00M | 2.41M | 1.63M | 1.29M |
Total Liabilities | 21.45M | 7.33M | 10.32M | 8.92M | 8.15M | 8.41M |
Stockholders Equity | 4.58M | 7.95M | 411.00K | 4.80M | 25.54M | 16.92M |
Cash Flow | ||||||
Free Cash Flow | -15.14M | -13.26M | -12.75M | -20.51M | -18.13M | -5.80M |
Operating Cash Flow | -14.42M | -12.69M | -11.95M | -19.59M | -15.73M | -5.68M |
Investing Cash Flow | -6.38M | -568.00K | -853.00K | -924.00K | -2.61M | -120.25K |
Financing Cash Flow | 18.30M | 17.88M | 10.92M | 0.00 | 24.17M | 23.54M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $17.67M | ― | -105.72% | ― | 0.09% | 51.09% | |
44 Neutral | $21.76M | ― | -262.03% | ― | 2.65% | 70.21% | |
44 Neutral | $16.65M | ― | -63.40% | ― | -91.14% | 9.47% | |
41 Neutral | $22.30M | ― | ― | ― | 15.00% | 71.57% | |
40 Underperform | $24.05M | ― | ― | ― | -26.49% | -91.23% |
Vivos Therapeutics Navigates Transition with Strategic Investments
Vivos Therapeutics, Inc. is a medical technology company specializing in proprietary oral appliances and therapeutic treatments for sleep disorders, particularly obstructive sleep apnea (OSA). The company operates in the healthcare sector and is known for its innovative, non-surgical solutions for maxillofacial abnormalities linked to breathing and sleep issues.
Vivos Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the recent acquisition of The Sleep Center of Nevada, which requires additional time for auditing and integration of financial statements. The company expects to file the report within the five-day extension period allowed by the SEC. Financially, Vivos anticipates a significant increase in general and administrative expenses, leading to a material rise in net loss for the quarter compared to the previous year, largely due to one-time acquisition costs. The company remains committed to compliance, with CFO Bradford Amman signing off on the notification.
The most recent analyst rating on (VVOS) stock is a Buy with a $6.60 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.